SH006

DRUG2 trials

Sponsors

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Conditions

Hepatocellular Carcinoma (HCC)Liver Cancer

Phase 1

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

Active, not recruitingNCT07362264

Nanjing Sanhome Pharmaceutical, Co., Ltd.Liver Cancer

Start: 2025-07-01End: 2028-12-30Target: 50Updated: 2026-01-23

Phase 2

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not yet recruitingNCT07392866

Nanjing Sanhome Pharmaceutical, Co., Ltd.Hepatocellular Carcinoma (HCC)

Start: 2026-03-01End: 2030-03-01Target: 120Updated: 2026-02-09